Quality of Life in Patients With Multiple Myeloma-validation Study
NCT ID: NCT03537222
Last Updated: 2021-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
58 participants
OBSERVATIONAL
2018-10-10
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MyPOS
Myeloma Patient Outcome Scale (MyPOS)
Patients complete the MyPOS questionnaire on quality of life
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myeloma Patient Outcome Scale (MyPOS)
Patients complete the MyPOS questionnaire on quality of life
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* confirmed histological diagnosis of multiple myeloma,
* age ≥ 18 years,
* mental capacity to give written informed consent
Exclusion Criteria
* participation in another clinical study
* more than one cancer diagnosis
* mental illness (i.e. psychiatric diagnosis)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kantonsspital Münsterlingen
OTHER
Kantonsspital Aarau
OTHER
Klinik Hirslanden, Zurich
OTHER
Celgene Corporation
INDUSTRY
King's College London
OTHER
Zurich University of Applied Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. med. Julia Dratva
Head of health sciences research unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia Dratva, Prof.Dr.med
Role: PRINCIPAL_INVESTIGATOR
Zurich University of Applied Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kantonsspital Aarau
Aarau, Canton of Zurich, Switzerland
Kantonsspital Münsterlingen
Münsterlingen, Thurgau, Switzerland
Onkozentrum Hirslanden
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
97107155001701
Identifier Type: -
Identifier Source: org_study_id